Core Viewpoint - HCA Healthcare Inc. is identified as one of the most undervalued large-cap stocks, with recent price target increases from RBC Capital and TD Cowen following strong Q4 2025 results and positive 2026 guidance [1][3] Group 1: Financial Performance - RBC Capital raised its price target for HCA Healthcare to $555 from $525, maintaining an Outperform rating, citing strong Q4 2025 results and robust 2026 guidance [1] - TD Cowen increased its price target from $490 to $529 with a Buy rating after HCA's Q4 2025 EBITDA exceeded consensus expectations, attributing this to effective expense controls [3] Group 2: Strategic Initiatives - HCA Healthcare is expected to achieve $400 million in savings from strategic resiliency initiatives, which will help offset challenges such as the expiration of enhanced premium tax credits and reduced contributions from state programs [1][2] - The company is leveraging its scale and data-driven efficiencies to drive growth despite a changing regulatory and payer landscape [2] Group 3: Company Overview - HCA Healthcare operates hospitals and related healthcare entities in the US, providing general and acute care services [4]

Core Insights - Ramsay Santé reported a revenue increase of 4.7% to €5.2 billion for the year ending June 30, 2025, driven by activity volume growth and acquisitions, despite a decrease in public funding [5][20][21] - Group EBITDA rose by 1.7% to €621 million, reflecting effective cost control measures and operational efficiency, despite challenges from reduced French grants and inflation [5][8][24] - The company continues to expand its healthcare services across Europe, reaching 13 million patients, with a focus on underserved areas in France [5][35][36] Financial Performance - Revenue increased from €5,006.5 million to €5,242.0 million, marking a 4.7% growth [10] - EBITDA grew from €610.9 million to €621.4 million, a 1.7% increase, with a margin of 11.9% [10][11] - The net loss attributable to owners of the company was stable at €54.1 million compared to €53.9 million the previous year [10][29] Operational Highlights - Ramsay Santé's French revenue grew by 5.9%, supported by the acquisition of 12 primary care centers and the opening of new mental health facilities [21][22] - The company achieved a record Net Promoter Score of 74% in France, indicating strong patient satisfaction [5] - Significant expansion in outpatient activities, including new primary care centers and mental health facilities, was noted [5][14] Strategic Developments - The company secured a long-term contract worth approximately €4.8 billion for St. Göran's Hospital in Stockholm, enhancing its operational footprint in Sweden [14] - Ramsay Santé successfully refinanced its senior debt facilities, extending maturities and optimizing pricing, which supports its strategic plan "Yes We Care 2025" [18][34] - The company continues to advocate for fair public funding to address industry-wide cost pressures and maintain quality care [8][9] Market Position - Ramsay Santé operates in five countries, with a strong presence in underserved areas, particularly in France where 60% of facilities are located in such regions [5][35] - The company is recognized for its commitment to improving healthcare access and quality, with ongoing investments in medical innovation and digital health solutions [36][37]